Betaferon
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Fingolimod is a novel immunomodulatory drug used in patients with relapsing multiple sclerosis (MS) which reversibly inhibits…
Introduction Adherence to treatment, including early treatment discontinuation, in patients with multiple sclerosis or clinically…
Introduction: Multiple sclerosis (MS) is a chronic neurologic disease. At the present time, Rebif, which is the most effective…
The BEtaferon®/BEtaseron® in Newly Emerging MS For Initial Treatment (BENEFIT) trial assessed the efficacy of early versus…
The immunological processes underlying immunogenicity of recombinant human therapeutics are poorly understood. Using an immune…
Objectives and methods – National guidelines for immunomodulatory treatment in multiple sclerosis (MS) were established in Norway…
BACKGROUND
The cognitive impairment (frontal, parietal) in many patients with multiple sclerosis does not correlate with the…
In last decades, practical neurologists are able to use DMT in multiple sclerosis (MS) in every day practice. This paper presents…
This follow-up study assessed the 2-year clinical and magnetic resonance imaging (MRI) outcomes of patients with multiple…
SUMMARY This study estimates the long-term cost effectiveness of Betaferon®, (interferon beta-1b) in the treatment of relapsing…